{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
PharmaCyte Biotech, Inc.
Is PharmaCyte Biotech, Inc. overvalued or undervalued?
As of October 3, 2023, PharmaCyte Biotech, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2 and price-to-book ratio of 5.6, especially when compared to peers like Amgen and Gilead, alongside its recent underperformance against the Sensex.
Is PharmaCyte Biotech, Inc. technically bullish or bearish?
As of October 5, 2023, there is not enough technical data for PharmaCyte Biotech, Inc. to determine if it is bullish or bearish.
What does PharmaCyte Biotech, Inc. do?
PharmaCyte Biotech, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit of -$3 million and a market cap of $7.28 million. Key metrics include a P/E ratio of 0.00 and a return on equity of 43.35%.
How big is PharmaCyte Biotech, Inc.?
As of Jun 18, PharmaCyte Biotech, Inc. has a market capitalization of 7.28 million, with net sales of 0.00 million and a net profit of 20.25 million over the latest four quarters. The company reported shareholder's funds of 39.51 million and total assets of 59.90 million as of Apr 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
